<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2327">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332042</url>
  </required_header>
  <id_info>
    <org_study_id>TOFACoV</org_study_id>
    <nct_id>NCT04332042</nct_id>
  </id_info>
  <brief_title>TOFAcitinib in SARS-CoV2 Pneumonia</brief_title>
  <official_title>TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Università Politecnica delle Marche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Università Politecnica delle Marche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to
      SARS-CoV2 infection. Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by
      blocking IL-6 signal. The aim of this prospective single cohort open study is to test the
      hypotesis that early administration of tofacitinib in patients with symptomatic pneumonia
      could reduce pulmonary flogosis, preventing function deterioration and the need of mechanical
      ventilation and/or admission in intensive care units.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interstitial Pneumonia is the main complication of SARS-CoV2 infection. Immune system
      hyperactivation, leading to alveolar inflammation, is the main mechanism in determining lung
      damage. Evidence are accumulating about the pivotal role played by IL-6 in this disease.
      Preliminary evidence, indeed, point out the efficacy of an IL-6 receptor inhibitor in
      improving clinical conditions in a proportion of rapidly deteriorating patients. Our
      hypotesis is that a precocious inhibition of IL-6 signal, by the administration of
      tofacitinib (JAK 1/3 Inhibitor), could hinder the progression to more severe grades of lung
      inflammation leading to pulmonary function deterioration. In a prospective single cohort open
      study, 50 patients admitted in Hospital due to SARS-CoV 2 symptomatic interstitial pneumonia,
      but not requiring mechanical ventilation, will be enrolled. Tofacitinb will be administered
      every day for 14 days, starting within 24 h from the admission. The primary outcome is to
      evaluate the effect of this drug on the rate of patients who will need mechanical
      ventilation. Safety in this population will also be actively monitored.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2020</start_date>
  <completion_date type="Anticipated">July 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>prospective cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>need of mechanical ventilation</measure>
    <time_frame>day 14</time_frame>
    <description>Rate of patients needing mechanical ventilation to maintain PaO2/FIO2&gt;150 or, if PaO2 data not available, to maintain SO2&gt;94% with FiO2 0,5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>need of admission in intensive care unit</measure>
    <time_frame>day 14</time_frame>
    <description>Rate of patients needing admission to the intensive care unit for oro-tracheal intubation and/or evidence of Multiple Organ Disfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death</measure>
    <time_frame>day 28</time_frame>
    <description>rate of patients dead</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of adverse events</measure>
    <time_frame>day 28</time_frame>
    <description>rate and type of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>SARS-COv2 Related Interstitial Pneumonia</condition>
  <arm_group>
    <arm_group_label>tofacitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tofacitinib cp 5mg: 2pills twice a day for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tofacitinib</intervention_name>
    <description>Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days</description>
    <arm_group_label>tofacitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  SARS-CoV2 Infection diagnosed by rt-PCR

          -  Rx or CT-scan confirmed interstitial pneumonia

          -  Hospital admission from less than 24h

          -  Written Informed Consent

        Exclusion Criteria:

          -  Age &lt;18 ys or &gt;65

          -  Patients in mechanical ventilation at time of admission

          -  Severe Hearth failure (NYHA 3 or 4)

          -  Severe History of Chronic Ischemic Hearth Disease, defined as history of Major Adverse
             Cardiovascular Event and/or recent (one year) revascularization.

          -  History of recurrent Deep Venous Thrombosis and Pulmonary Embolism

          -  Active Bacterial or Fungal Infection

          -  Hematological cancer

          -  Metastatic or intractable cancer

          -  Pre-existent neurodegenerative disease

          -  Severe Hepatic Impairment

          -  Severe Renal Failure (Creatinine Clearance &lt;30ml/h)

          -  Active Herpes zoster infection

          -  Severe anemia (Hb&lt;9g/dl)

          -  Lymphocyte count below 750/mcl

          -  Neutrophil count below 1000/mcl

          -  Platelet count below 50000/mcl

          -  Pregnancy or Lactation

          -  Inability to give informed consent (severe transitory or permanent mental impairment,
             incapacitation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedali Riuniti di Ancona</name>
      <address>
        <city>Ancona</city>
        <state>Marche</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Armando Gabrielli, Prof</last_name>
      <phone>+390712206104</phone>
      <email>a.gabrielli@staff.univpm.it</email>
    </contact>
    <investigator>
      <last_name>Armando Gabrielli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovanni Pomponio, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.</citation>
    <PMID>32114094</PMID>
  </reference>
  <reference>
    <citation>Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020 Mar 4;9(3). pii: E186. doi: 10.3390/pathogens9030186. Review.</citation>
    <PMID>32143502</PMID>
  </reference>
  <reference>
    <citation>Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5.</citation>
    <PMID>32035018</PMID>
  </reference>
  <reference>
    <citation>Rose-John S, Scheller J, Schaper F. &quot;Family reunion&quot;--A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines. Cytokine Growth Factor Rev. 2015 Oct;26(5):471-4. doi: 10.1016/j.cytogfr.2015.07.011. Epub 2015 Jul 6.</citation>
    <PMID>26235233</PMID>
  </reference>
  <reference>
    <citation>McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.</citation>
    <PMID>31375130</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Università Politecnica delle Marche</investigator_affiliation>
    <investigator_full_name>Armando Gabrielli</investigator_full_name>
    <investigator_title>Full Professor Internal Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

